3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
35
Advanced Solid Tumors
20
Carcinoma, Non-Small-Cell Lung
14
Myelodysplastic Syndromes
13
Breast Neoplasms
13
Advanced Solid Tumor
13
Recurrence
10
Ovarian Neoplasms
8
Neoplasms
8
Multiple Myeloma
8
Leukemia, Myelomonocytic, Chronic
8
Triple Negative Breast Neoplasms
7
Solid Tumor
6
Myeloproliferative Disorders
6
Small Cell Lung Carcinoma
5
Prostatic Neoplasms
5
Neoplasm Metastasis
5
Lung Neoplasms
5
Carcinoma, Hepatocellular
5
Advanced Solid Tumour
5
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Melanoma
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, B-Cell
4
Fallopian Tube Neoplasms
4
Colorectal Neoplasms
4
Advanced Malignant Solid Tumor
4
Advanced Lung Cancer
4
Squamous Cell Carcinoma of Head and Neck
3
Interventions
Capecitabine
41
Oxaliplatin
39
Fluorouracil
29
Leucovorin
23
Radiotherapy
21
Cetuximab
14
Bevacizumab
14
Irinotecan
13
Nivolumab
12
Magnetic Resonance Spectroscopy
11
Specimen Handling
9
Surgical Procedures, Operative
8
Folfox protocol
8
Drug Therapy
8
pembrolizumab
7
Radiotherapy, Intensity-Modulated
7
Chemoradiotherapy
7
Biopsy
7
trifluridine tipiracil drug combination
6
Radiation
6
tislelizumab
5
sintilimab
5
regorafenib
5
dehydroftorafur
5
X-Rays
5
Surveys and Questionnaires
5
Sigmoidoscopy
5
Endoscopy
5
Consolidation Chemotherapy
5
spartalizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rectal Neoplasms
×
Injections
×
1 year
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled